Clear cell carcinoma of the ovary: A review of the literature

Carmen, Marcela G. del; Birrer, Michael J.; Schorge, John O.

doi:10.1016/j.ygyno.2012.04.021

Cited by 217 publications

(198 citation statements)

References 112 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…1,2 Accumulating evidence suggests that OCCC has distinct clinical and molecular characteristics compared with other histologic subtypes of epithelial ovarian cancer. 3,4 Clinically, patients with advanced-stage OCCC have poorer survival outcomes than those with advanced-stage serous ovarian carcinoma (SOC), whereas patients with early-stage OCCC and SOC have similar survival outcomes. 5,6 However, the reasons for this discrepancy and the mechanisms leading to poor survival outcomes in patients with advanced-stage OCCC have yet to be completely elucidated.…”

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Matsuo¹,

Hasegawa²,

Yoshino³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Matsuo¹,

Hasegawa²,

Yoshino³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…1 Compared with high-grade serous adenocarcinomas, ovarian clear cell carcinomas are characterized by a higher incidence among Asians, younger patient age and early tumor staging at presentation, association with endometriosis, higher frequencies of AT-rich interactive domain 1 A (ARID1A) mutation and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, and higher resistance to first-line platinum and taxane-based chemotherapy. [2][3][4] Primary endometrial clear cell carcinoma (which has similar histologic characteristics to ovarian clear cell carcinoma) is a rare histologic type that accounts for less than 3% of all endometrial carcinomas. 5,6 Interobserver reproducibility of endometrial clear cell carcinoma was poor, 7,8 and a panel of hepatocyte nuclear factor-1b (HNF-1b) and estrogen receptor (ER) immunohistochemistry was suggested for differentiation of endometrial clear cell carcinoma from endometrioid and serous carcinoma.…”

mentioning

confidence: 99%

Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation

et al. 2015

View full text Add to dashboard Cite

Recently, mutations of telomerase reverse transcriptase (TERT) promoter were found in several types of cancer. A few reports demonstrate TERT promoter mutations in ovarian clear cell carcinomas but endometrial clear cell carcinoma has not been studied. The aims of this study were to compare differences of molecular alterations and clinical factors, and identify their prognostic impact in endometrial and ovarian clear cell carcinomas. We evaluated mutations of the TERT promoter and PIK3CA, expression of ARID1A, and other clinicopathological factors in 56 ovarian and 14 endometrial clear cell carcinomas. We found that TERT promoter mutations were present in 21% (3/14) of endometrial clear cell carcinomas and 16% (9/56) of ovarian clear cell carcinomas. Compared with ovarian clear cell carcinomas, endometrial clear cell carcinomas showed older mean patient age (Po0.001), preserved ARID1A immunoreactivity (P ¼ 0.017) and infrequent PIK3CA mutation (P ¼ 0.025). In ovarian clear cell carcinomas, TERT promoter mutations were correlated with patient age 445 (P ¼ 0.045) and preserved ARID1A expression (P ¼ 0.003). In cases of endometrial clear cell carcinoma, TERT promoter mutations were not statistically associated with any other clinicopathological factors. In ovarian clear cell carcinoma patients with early FIGO stage (stages I and II), TERT promoter mutation was an independent prognostic factor and correlated with a shorter disease-free survival and overall survival (P ¼ 0.015 and 0.009, respectively). In recurrent ovarian clear cell carcinoma patients with early FIGO stage, TERT promoter mutations were associated with early relapse within 6 months (P ¼ 0.018). We concluded that TERT promoter mutations were present in endometrial and ovarian clear cell carcinomas. Distinct molecular alteration patterns in endometrial and ovarian clear cell carcinomas implied different processes of tumorigenesis in these morphologically similar tumors. In ovarian clear cell carcinoma of early FIGO stage, patients with TERT promoter mutation require close follow-up during the initial 6 months following chemotherapy. Modern Pathology (2015) 28, 303-311; doi:10.1038/modpathol.2014 published online 1 August 2014 Ovarian clear cell carcinoma represents 5-25% of all epithelial ovarian carcinomas with geographic variation. 1 Compared with high-grade serous adenocarcinomas, ovarian clear cell carcinomas are characterized by a higher incidence among Asians, younger patient age and early tumor staging at presentation, association with endometriosis, higher frequencies of AT-rich interactive domain 1 A (ARID1A) mutation and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, and higher resistance to first-line platinum and taxane-based chemotherapy.

show abstract

“…1,2 Because patients with early stage CCA may have a similar or better prognosis than patients with high grade ovarian serous tumors, early detection by imaging is important. 1,2 A high frequency of concurrent endometriosis is one characteristic of CCA, and endometrioma is considered a precursor of CCA.…”

Section: Introductionmentioning

confidence: 99%

Clear Cell Adenocarcinoma Arising from Clear Cell Adenofibroma of the Ovary: Value of DWI and DCE-MRI

et al. 2013

View full text Add to dashboard Cite

Clear cell adenoˆbroma (CCAF) is a rare surface epithelial-stromal tumor of the ovary and recently considered another precursor of clear cell adenocarcinoma (CCA) other than endometrioma. We report magnetic resonance (MR)ˆndings of a borderline CCAF that contained a small CCA focus. The tumor manifested a characteristic``black sponge'' appearance. The CCA focus showed high signal intensity on diŠusion-weighted imaging (DWI) and early enhancement on dynamic contrast-enhanced (DCE) MR imaging (DCE-MRI), and the CCAF components showed low signal intensity on DWI and gradually increasing contrast enhancement on DCE-MRI.

show abstract

Clear cell carcinoma of the ovary: A review of the literature

Cited by 217 publications

References 112 publications

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma

Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation

Clear Cell Adenocarcinoma Arising from Clear Cell Adenofibroma of the Ovary: Value of DWI and DCE-MRI

Contact Info

Product

Resources

About